Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Withdrawn 2Terminated 2Recruiting 2No longer available 1

Sponsor Class

INDUSTRY 6OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Recurrence 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × ganitumab × Clear all
NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Dana-Farber Cancer Institute

Phase 2 Terminated
10 enrolled 15 charts
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing

NCT00718523 2016-01-12

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Translational Research in Oncology

Phase 2 Terminated
170 enrolled 20 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡